🔎 Trials Near Me

Home › Ewing Sarcoma › Tennessee › Memphis

Ewing Sarcoma clinical trials in Memphis, TN

7 studies for Ewing Sarcoma are looking for participants at sites in and around Memphis (within about 30 miles). Open a study to see who can join and how to contact the study team.

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Saint Jude Children's Research Hospital, Memphis
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

Recruiting
  • St. Jude Children's Research Hospital, Memphis
All ages · All sexes · Updated Aug 21, 2026 · NCT07514819

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
  • St. Jude Children's Research Hospital, Memphis
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

RecruitingPhase 1
  • St. Jude Children's Research Hospital, Memphis
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

RecruitingPhase 1
  • St. Jude Children's Research Hospital, Memphis
Up to age 21 · All sexes · Updated Feb 9, 2026 · NCT07222735

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

RecruitingPhase 1/2
  • St. Jude Children's Research Hospital, Memphis
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066

Molecular Analysis Of Solid Tumors

RecruitingObservational study
  • St. Jude Children's Research Hospital, Memphis
Up to age 25 · All sexes · Updated Nov 12, 2025 · NCT01050296

Ewing Sarcoma trials in other cities

Other studies in Memphis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.